Mammary Cell News Volume 4.20 | May 24 2012

LABORATORY RESEARCH

Lunatic Fringe Deficiency Cooperates with the Met/Caveolin Gene Amplicon to Induce Basal-Like Breast Cancer
Notch receptor signaling promotes luminal cell fate specification in the mammary gland, while suppressing stem cell self-renewal. Researchers showed that deletion of Lfng, a sugar transferase that prevents Notch activation by Jagged ligands, enhances stem/progenitor cell proliferation. [Cancer Cell] Abstract

The Stat6-Regulated KRAB Domain Zinc Finger Protein Zfp157 Regulates the Balance of Lineages in Mammary Glands and Compensates for Loss of Gata-3
Researchers showed that zinc finger protein 157 (Zfp157) is required to establish the balance between luminal alveolar pStat5- and Gata-3-expressing cells in the murine mammary gland. [Genes Dev]
Abstract | Full Article

Orally Bioavailable Small-Molecule Inhibitor of Transcription Factor Stat3 Regresses Human Breast and Lung Cancer Xenografts
Researchers found that intravenous or oral gavage delivery of BP-1-102 furnishes micromolar or microgram levels in tumor tissues and inhibits growth of human breast and lung tumor xenografts. [Proc Natl Acad Sci USA] Abstract | Full Article

Mevalonate Metabolism Regulates Basal Breast Cancer Stem Cells and Is a Potential Therapeutic Target
Researchers sought to identify specific molecular pathways of cancer stem cells isolated from 13 different breast cancer cell lines of luminal or basal/mesenchymal subtypes. They compared the gene expression profiling of cancer cells grown in adherent conditions to those of matched tumorsphere cultures. [Stem Cells] Abstract

CD44 Enhances Invasion of Basal-Like Breast Cancer Cells by Up-Regulating Serine Protease and Collagen-Degrading Enzymatic Expression and Activity
Researchers found that hyaluronan-induced CD44 signaling increases a diverse spectrum of protease activity to facilitate the invasion associated with basal-like breast cancers cells, providing new insights into the molecular basis of CD44-promoted invasion. [Breast Cancer Res] Abstract | Full Article

FES Kinase Promotes Mast Cell Recruitment to Mammary Tumors via the Stem Cell Factor/KIT Receptor Signaling Axis
Researchers investigated whether FES protein-tyrosine kinase, a downstream effector of KIT signaling in mast cells (MCs), is required for migration of MCs towards stem cell factor-expressing mammary tumors. [Mol Cancer Res] Abstract

CLINICAL RESEARCH

JMJD6 Is a Driver of Cellular Proliferation and Motility and a Marker of Poor Prognosis in Breast Cancer
Researchers developed an analytical strategy that correlates gene expression and clinical outcomes as a means to identify novel candidate oncogenes operative in breast cancer. This analysis, followed by functional characterization, resulted in the identification of Jumonji Domain Containing 6 (JMJD6) protein as a novel driver of oncogenic properties in breast cancer. [Breast Cancer Res] Abstract | Full Article

Local-Regional Control According to Surrogate Markers of Breast Cancer Subtypes and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast Conserving Therapy
The goal of this study was to identify patients at high risk for local-regional recurrence according to response to neoadjuvant chemotherapy and surrogate markers of molecular subtypes in patients undergoing breast conserving therapy. [Breast Cancer Res] Abstract | Full Article

Celldex’s CDX-011 Demonstrates High Response Rates in Patients with Metastatic Breast Cancer Expressing Elevated Levels of GPNMB and in Triple Negative Disease
Celldex Therapeutics, Inc. announced preliminary results from the Company’s randomized Phase IIb EMERGE study of CDX-011 (glembatumumab vedotin) antibody drug conjugate in patients with glycoprotein NMB (GPNMB) expressing advanced, heavily pretreated breast cancer. [Celldex Therapeutics, Inc.]
Press Release

Texas Researchers Studying Breast Cancer Prevention, Minorities and More Effective Treatments with $8.4 Million in New Research Funding from Susan G. Komen for the Cure^®
Texas breast cancer researchers will share $8.4 million in new research dollars to develop breakthrough drugs for common breast cancers, more effectively treat advanced forms of the disease, and improve breast cancer outcomes for Latinas, with 2012 research funding from Susan G. Komen for the Cure^®. [Business Wire] Press Release

World’s First Approved Stem Cell Drug; Osiris Receives Marketing Clearance from Health Canada for Prochymal
Osiris Therapeutics Inc. announced that it has received market authorization from Health Canada to market its stem cell therapy Prochymal^® (remestemcel-L) for the treatment of acute graft-vs-host disease in children. [Osiris Therapeutics, Inc.] Press Release 

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW International Society for Cellular Therapy (ISCT) 18^th Annual Meeting
June 5-8, 2012
Seattle, United States

Visit our events page to see a complete list of events in the mammary cell community.

Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

Scientist – Endothelial Cells (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – hPSC Bioengineering (STEMCELL Technologies Inc.)

Scientist – Antibody and Hybridoma Technology Platforms (STEMCELL Technologies Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Business Analyst – Product Management (STEMSOFT Software Inc.)

Postdoctoral Position – Translational Breast Cancer Research (ISREC/EPFL)

Postdoctoral Position – Breast Cancer Biology (Bellvitge Institute for Biomedical Research)

Postdoc Positions – Molecular Cancer Biology (Baylor College of Medicine)

Postdoctoral Position – Breast Cancer Research (Beckman Research Institute)

Research Fellowship – Transformed Signal Transduction Networks in Breast Cancer (Memorial Sloan-Kettering Cancer Center)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.